Company Description
Quest Diagnostics is testing its ability to be the world's leading clinical lab. The company performs tests on about 150 million specimens each year,...
Key Quest Diagnostics Financials
| Company Type | Public - NYSE: DGX Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $6,704.9 |
| 2007 Employees | 43,500 |
More Quest Diagnostics Financials (11 pages)
Latest Quest Diagnostics Jobs jobs by Indeed
Rankings
- #365 in FORTUNE 500
- S&P 500
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Quest Diagnostics's competition across multiple industries
Top Quest Diagnostics Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Quest Diagnostics Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman, President, and CEO | Surya N. Mohapatra | Network | E-mail |
| SVP and CFO | Robert A. Hagemann | Network | E-mail |
| SVP and General Counsel | Michael E. Prevoznik | Network | E-mail |
More Quest Diagnostics Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Quest Diagnostics News
- Federal Register [Federal Register] (03 Jul 2008 00:01:00 EDT)
- Health and Human Services Department Documents and Publications [Health & Human Services Department & Publications] (03 Jul 2008 00:01:00 EDT)
- [DIAG]-FDA grants CLIA waiver for HemoCue Albumin 201 test [AHC Newsletters] (03 Jul 2008 00:01:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.